The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells

(2018) Varun Sasidharan Nair et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions

(2018) Smriti Kanangat et al.   HUMAN IMMUNOLOGY

Dexmedetomidine promotes liver regeneration in mice after 70% partial hepatectomy by suppressing NLRP3 inflammasome not TLR4/NFκB

(2018) Meihong Lv et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells

(2018) Sadamu Homma et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Tryptase promotes breast cancer angiogenesis through PAR‑2 mediated endothelial progenitor cell activation

(2018) Neng Qian et al.   Oncology Letters

Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies

(2018) Daisuke Minakata et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells

(2018) Hiroshi Sugano et al.   Cancers

An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling

(2017) Po-Lin Lin et al.   EUROPEAN JOURNAL OF CANCER

Tryptase inhibitors: a patent review

(2017) Wei-Wei Ni et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation

(2017) Sheema Almozyan et al.   INTERNATIONAL JOURNAL OF CANCER

Quinacrine Inhibits ICAM-1 Transcription by Blocking DNA Binding of the NF-κB Subunit p65 and Sensitizes Human Lung Adenocarcinoma A549 Cells to TNF-α and the Fas Ligand

(2017) Misuzu Harada et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Impaired angiopoietin/Tie2 signaling compromises Schlemm’s canal integrity and induces glaucoma

(2017) Jaeryung Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Proteasome inhibitors in cancer therapy

(2017) Elisabet E. Manasanch et al.   Nature Reviews Clinical Oncology

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

(2017) M. Wroblewski et al.   Nature Communications

SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells

(2017) Zhuqing Liu et al.   Oncotarget

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

(2017) James W. Smithy et al.   Journal for ImmunoTherapy of Cancer

Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin

(2016) Ju Yong Lim et al.   ANNALS OF THORACIC SURGERY

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

(2016) Mizuki Yamamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death

(2016) Alice Borghi et al.   BIOCHEMICAL PHARMACOLOGY

Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats

(2016) Chenhui Li et al.   BRAIN BEHAVIOR AND IMMUNITY

Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer

(2016) Yoshihiro Shirai et al.   CANCER LETTERS

VEGF/NRP-1 axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin

(2016) Minna Luo et al.   CANCER LETTERS

Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis

(2016) Yun-Xin Lu et al.   CANCER LETTERS

Blockade of high mobility group box 1 augments antitumor T-cell response induced by peptide vaccination as a co-adjuvant

(2016) Kayoko Waki et al.   CANCER SCIENCE

Curcumol Suppresses Breast Cancer Cell Metastasis by Inhibiting MMP-9 Via JNK1/2 and Akt-Dependent NF-κB Signaling Pathways

(2016) Ling Ning et al.   INTEGRATIVE CANCER THERAPIES

Comparison of Nafamostat Mesilate and Unfractionated Heparin as Anticoagulants during Continuous Renal Replacement Therapy

(2016) Shohei Makino et al.   INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS

New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer

(2016) Takashi Horiuchi et al.   JOURNAL OF SURGICAL RESEARCH

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway

(2016) Sujeong Choi et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer

(2016) Qing Chen et al.   NATURE

Nafamostat mesilate protects against acute cerebral ischemia via blood–brain barrier protection

(2016) Jing Wang et al.   NEUROPHARMACOLOGY

Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study

(2016) Koji Sawada et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Noncanonical NF-κB Signaling in Health and Disease

(2016) Gökhan Cildir et al.   TRENDS IN MOLECULAR MEDICINE

Characterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species

(2015) Chih-Yuan Chiang et al.   BMC MICROBIOLOGY

NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis

(2015) L Boutaffala et al.   CELL DEATH AND DIFFERENTIATION

Tryptase, a novel angiogenic factor stored in mast cell granules

(2015) Domenico Ribatti et al.   EXPERIMENTAL CELL RESEARCH

Nafamostat Mesilate as a Regional Anticoagulant in Patients with Bleeding Complications during Extracorporeal Membrane Oxygenation

(2015) Jin-Han Park et al.   INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk

(2015) Ji-Young Choi et al.   MEDICINE

Human mast cell tryptase in biology and medicine

(2015) Joana Vitte   MOLECULAR IMMUNOLOGY

Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation

(2015) Yinghui Li et al.   NATURE CELL BIOLOGY

A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease

(2015) Hidekazu Nishimura et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis

(2015) Devandir Antonio de Souza Junior et al.   Biomed Research International

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

(2014) Laura Tornatore et al.   CANCER CELL

The Effect of Serine Protease Inhibitors on Airway Inflammation in a Chronic Allergen-Induced Asthma Mouse Model

(2014) Chih-Che Lin et al.   MEDIATORS OF INFLAMMATION

Regulation of NF-κB by TNF family cytokines

(2014) Matthew S. Hayden et al.   SEMINARS IN IMMUNOLOGY

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition

(2014) Tao Chen et al.   Scientific Reports

Targeting Mast Cells Tryptase in Tumor Microenvironment: A Potential Antiangiogenetic Strategy

(2014) Michele Ammendola et al.   Biomed Research International

Mast cell activation syndromes: definition and classification

(2013) P. Valent   ALLERGY

Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer

(2013) Takeshi Gocho et al.   CANCER LETTERS

Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis

(2013) Hiroki Yuhara et al.   JOURNAL OF GASTROENTEROLOGY

Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation

(2013) Ryota Iwase et al.   JOURNAL OF SURGICAL RESEARCH

The complexity of NF-κB signaling in inflammation and cancer

(2013) Bastian Hoesel et al.   Molecular Cancer

Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice

(2013) Koichiro Haruki et al.   SURGERY

Inhibition of Nuclear Factor-κB Enhances the Antitumor Effect of Paclitaxel Against Gastric Cancer with Peritoneal Dissemination in Mice

(2012) Koichiro Haruki et al.   DIGESTIVE DISEASES AND SCIENCES

Inhibition of Nuclear Factor Kappa-B Enhances the Antitumor Effect of Combination Treatment with Tumor Necrosis Factor-Alpha Gene Therapy and Gemcitabine for Pancreatic Cancer in Mice

(2012) Yuki Fujiwara et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations

(2012) Giovanni Brandi et al.   PLoS One

Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis

(2012) Robert D Inman et al.   ARTHRITIS RESEARCH & THERAPY

Phase II Study of Gemcitabine in Combination With Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic Cancer

(2011) Tadashi Uwagawa et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition

(2011) Yuki Fujiwara et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Combination Paclitaxel and Inhibitor of Nuclear Factor κB Activation Improves Therapeutic Outcome for Model Mice With Peritoneal Dissemination of Pancreatic Cancer

(2011) Yuki Fujiwara et al.   PANCREAS

Anti-tumor effect by inhibition of NF-κB activation using nafamostat mesilate for pancreatic cancer in a mouse model

(2010) Furukawa   ONCOLOGY REPORTS

The Complement Inhibitor FUT-175 Suppresses T Cell Autoreactivity in Experimental Autoimmune Encephalomyelitis

(2009) Qing Li et al.   AMERICAN JOURNAL OF PATHOLOGY

A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer

(2008) T. Uwagawa et al.   ANNALS OF ONCOLOGY